Literature DB >> 33483464

CSN6 promotes melanoma proliferation and metastasis by controlling the UBR5-mediated ubiquitination and degradation of CDK9.

Yanli Zhang1,2, Jianbing Hou2,3,4,5, Shaomin Shi1,2, Juan Du1,2, Yudong Liu2,3,4,5, Pan Huang2,3,4,5, Qian Li1,2, Lichao Liu1,2, Huanrong Hu1,2, Yacong Ji1, Leiyang Guo1, Yaqiong Shi1, Yaling Liu6, Hongjuan Cui7,8,9,10.   

Abstract

As a critical subunit of the constitutive photomorphogenesis 9 (COP9) signalosome (CSN), CSN6 is upregulated in some human cancers and plays critical roles in tumorigenesis and progression, but its biological functions and molecular mechanisms in melanoma remain unknown. Our study showed that CSN6 expression was upregulated in melanoma patients and cells, and correlated with poor survival in melanoma patients. In melanoma cells, CSN6 knockdown remarkably inhibited cell proliferation, tumorigenicity, migration, and invasion, whereas CSN6 recovery rescued the proliferative and metastatic abilities. Notably, we identified that CSN6 stabilized CDK9 expression by reducing CDK9 ubiquitination levels, thereby activating CDK9-mediated signaling pathways. In addition, our study described a novel CSN6-interacting E3 ligase UBR5, which was negatively regulated by CSN6 and could regulate the ubiquitination and degradation of CDK9 in melanoma cells. Furthermore, in CSN6-knockdown melanoma cells, UBR5 knockdown abrogated the effects caused by CSN6 silencing, suggesting that CSN6 activates the UBR5/CDK9 pathway to promote melanoma cell proliferation and metastasis. Thus, this study illustrates the mechanism by which the CSN6-UBR5-CDK9 axis promotes melanoma development, and demonstrate that CSN6 may be a potential biomarker and anticancer target in melanoma.

Entities:  

Year:  2021        PMID: 33483464      PMCID: PMC7822921          DOI: 10.1038/s41419-021-03398-0

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  44 in total

Review 1.  Secrets of a double agent: CDK7 in cell-cycle control and transcription.

Authors:  Robert P Fisher
Journal:  J Cell Sci       Date:  2005-11-15       Impact factor: 5.285

2.  Role of TAZ as mediator of Wnt signaling.

Authors:  Luca Azzolin; Francesca Zanconato; Silvia Bresolin; Mattia Forcato; Giuseppe Basso; Silvio Bicciato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Cell       Date:  2012-12-13       Impact factor: 41.582

3.  YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response.

Authors:  Luca Azzolin; Tito Panciera; Sandra Soligo; Elena Enzo; Silvio Bicciato; Sirio Dupont; Silvia Bresolin; Chiara Frasson; Giuseppe Basso; Vincenza Guzzardo; Ambrogio Fassina; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Cell       Date:  2014-06-26       Impact factor: 41.582

4.  CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis.

Authors:  Jiaqi Shi; Xin Guan; Fei Zhan; Chao Liu; Zhiwei Li; Yuanfei Yao; Bojun Wang; Changjie Lou; Yanqiao Zhang
Journal:  Cancer Biol Ther       Date:  2019-07-16       Impact factor: 4.742

5.  HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53.

Authors:  Yuwen Xue; Jian Chen; Hyun-Ho Choi; Liem Phan; Ping-Chieh Chou; Ruiying Zhao; Huiling Yang; Janice Santiago; Mo Liu; Giselle E Yeung; Sai-Ching J Yeung; Mong-Hong Lee
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

6.  EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer.

Authors:  Jennifer L Clancy; Michelle J Henderson; Amanda J Russell; David W Anderson; Ronaldo J Bova; Ian G Campbell; David Y H Choong; Graeme A Macdonald; Graham J Mann; Tania Nolan; Ged Brady; Olufunmilayo I Olopade; Erica Woollatt; Michael J Davies; Davendra Segara; Neville F Hacker; Susan M Henshall; Robert L Sutherland; Colin K W Watts
Journal:  Oncogene       Date:  2003-08-07       Impact factor: 9.867

Review 7.  Cyclin-dependent kinases.

Authors:  Marcos Malumbres
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

Review 8.  Current state of melanoma diagnosis and treatment.

Authors:  Lauren E Davis; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2019-08-01       Impact factor: 4.742

Review 9.  Regulation of CDK9 activity by phosphorylation and dephosphorylation.

Authors:  Sergei Nekhai; Michael Petukhov; Denitra Breuer
Journal:  Biomed Res Int       Date:  2014-01-12       Impact factor: 3.411

10.  Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma.

Authors:  Jing Zhang; Shenglan Liu; Qianyun Ye; Jingxuan Pan
Journal:  Mol Cancer       Date:  2019-09-16       Impact factor: 27.401

View more
  4 in total

1.  UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer.

Authors:  Gang Xiang; Shuxuan Wang; Ling Chen; Mei Song; Xiaoxu Song; Huan Wang; Pengbo Zhou; Xiaojing Ma; Jing Yu
Journal:  Cell Death Dis       Date:  2022-05-12       Impact factor: 9.685

2.  Targeted Nanotherapeutics Using LACTB Gene Therapy Against Melanoma.

Authors:  Jinlu Liu; Ling Yang; Xin Yuan; Meimei Xiong; Jiao Zhu; Wenbi Wu; Min Ren; Jianlin Long; Xuewen Xu; Maling Gou
Journal:  Int J Nanomedicine       Date:  2021-11-17

Review 3.  Targeting the COP9 signalosome for cancer therapy.

Authors:  Wenqi Du; Ruicheng Zhang; Bilal Muhammad; Dongsheng Pei
Journal:  Cancer Biol Med       Date:  2022-03-21       Impact factor: 5.347

Review 4.  Targeting CDK9 for Anti-Cancer Therapeutics.

Authors:  Ranadip Mandal; Sven Becker; Klaus Strebhardt
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.